Health Care & Life Sciences » Biotechnology | Gilead Sciences Inc.

Gilead Sciences Inc. | Cash Flow

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
3,057
12,059
18,106
13,488
4,644
5,460
Depreciation, Depletion & Amortization
345
1,050
1,098
1,158
1,286
1,429
Other Funds
431
3,677
3,095
745
330
2,161
Funds from Operations
3,668
13,336
19,170
15,501
6,790
9,339
Changes in Working Capital
563
518
1,159
1,546
5,108
939
Net Operating Cash Flow
3,105
12,818
20,329
17,047
11,898
8,400
Capital Expenditures
191
557
747
748
590
Purchase/Sale of Investments
315
1,266
11,728
11,237
5,053
Net Investing Cash Flow
254
1,823
12,475
11,985
16,069
Cash Dividends Paid - Total
-
-
1,874
2,455
2,731
Issuance/Reduction of Debt, Net
2,705
5,670
9,689
4,268
7,174
Net Financing Cash Flow
2,544
3,025
4,963
9,725
3,393
Net Change in Cash
309
7,914
2,824
4,622
641
Free Cash Flow
2,914
12,261
19,582
16,299
11,308
Deferred Taxes & Investment Tax Credit
98
236
393
119
82
289
Net Assets from Acquisitions
379
-
-
-
10,426
Change in Capital Stock
269
5,018
9,683
10,793
720
Exchange Rate Effect
2
56
67
41
137

About Gilead Sciences

View Profile
Address
333 Lakeside Drive
Foster City California 94404
United States
Employees -
Website http://www.gilead.com
Updated 07/08/2019
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. It also offers other pharmaceutical products under the Letairis, Ranexa, AmBisome, and Zydelig brands.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.